Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12284392 | 0.87 | PRMT1 (0.44) | ATMSMN1; SMN2ALDH1A1ITGB3ITGA2B | |
| SCHEMBL27336659 | 0.84 | GNAI3 (0.41) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL14980274 | 0.84 | GNAI3 (0.44) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL1775928 | 0.84 | GNAI3 (0.42) | ATMMEN1KMT2ASMN1; SMN2CYP1A2 | |
| SCHEMBL15355591 | 0.81 | GNAI3 (0.41) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL12283544 | 0.81 | ALDH1A1 (0.51) | L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL19464837 | 0.81 | HRH3 (0.42) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL1775192 | 0.81 | ATM (0.39) | ATMITGB3ITGA2B | |
| SCHEMBL22620788 | 0.80 | GNAI3 (0.40) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL20032529 | 0.79 | GNAI3 (0.40) | ATML3MBTL1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395309-A1 | PEPTIDE-DRUG CONJUGATES | HONG KONG BAPTIST UNIVERSITY (CN) | 2021-12-23 | — | — | US | disclosed |
| EP-3247405-B1 | SYNTHETIC APELIN FATTY ACID CONJUGATES WITH IMPROVED HALF-LIFE | NOVARTIS AG (CH) | 2019-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395309-A1 | PEPTIDE-DRUG CONJUGATES | BDKRB1, VIP, BDKRB2 | ATM 3299/4885L3MBTL1 2893/4885MEN1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.